Mayra Betancourt Ponce

Mayra Betancourt Ponce

Auto-generated profile, based on publicly available information

Mayra Betancourt Ponce

University of Wisconsin School of Medicine and Public Health Madison Wisconsin USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2026 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
MPMayra Betancourt Ponce
Mayra Betancourt Ponce
AHAlexa R. Heaton
Alexa R. Heaton
SBSamantha K. Burkard
Samantha K. Burkard
ADAurora D’AMato
Aurora D’AMato
NBNicha Boonpattrawong
Nicha Boonpattrawong
LBLisa Barroilhet
Lisa Barroilhet

24 June 2024 in Contact Dermatitis
Verified
Journal Article
Open access
MPMayra Betancourt Ponce
Mayra Betancourt Ponce
ESEric Schauberger
Eric Schauberger
ECEllen Connor
Ellen Connor
MRMargo Reeder
Margo Reeder

12 September 2025 in bioRxiv
Verified
Preprint
Open access
MPMayra Betancourt Ponce
Mayra Betancourt Ponce
AHAlexa R. Heaton
Alexa R. Heaton
SBSamantha K. Burkard
Samantha K. Burkard
ADAurora D’AMato
Aurora D’AMato
NBNicha Boonpattrawong
Nicha Boonpattrawong
LBLisa Barroilhet
Lisa Barroilhet
Melanoma continues to be the deadliest form of skin cancer, emphasizing the need for new therapeutic strategies. Targeting tumor metabolism, particularly oxidative phosphorylation (OXPHOS) has emerged as a promising approach due its role in melanoma tumor survival, metastasis, and treatment resistance. In this study, we investigate the metabolic and antitumor effects of atovaquone, an FDA-approved and safe OXPHOS inhibitor that has not been previously tested in melanoma. We show that atovaquone rapidly and effectively inhibits OXPHOS and impairs glycolysis in melanoma, leading to metabolic reprogramming observed via metabolic imaging and marked depletion in energy (ATP) stores. Atovaquone also induces oxidative stress, evidenced by increased reactive oxygen species levels, DNA damage, and upregulation of antioxidant proteins. Moreover, atovaquone reduced melanoma cell viability and migration in vitro , and slowed tumor growth in vivo . Notably, these effects were observed in both BRAF -wild-type and mutant melanoma models, suggesting its potential as an effective treatment across different subtypes. Our study identifies atovaquone as a metabolic disruptor with antitumor activity against melanoma, supporting further investigation as a repurposed therapeutic strategy.

29 June 2025 in Contact Dermatitis
Verified
Journal Article
Open access
MPMayra Betancourt Ponce
Mayra Betancourt Ponce
MRMargo Reeder
Margo Reeder